Study Finds THC-Dominant Marijuana Extract Improves Symptoms in Alzheimer’s Patients

Using THC-dominant marijuana extracts twice a day is associated with symptom mitigation in patients with Alzheimer’s disease

This is according to an observational study published in the Italian journal La Clinica Terapeutica.

For the study researchers examined the safety and efficacy of marijuana extract containing 22% THC and 0.5% CBD in 30 patients with mild to severe Alzheimer’s disease. Study participants administered the extracts twice daily for 12 weeks.

Investigators reported reductions in patients’ agitation, apathy, irritability, sleep disturbances, and eating disturbances following cannabis treatment. It also resulted in “lower levels of physically and verbally aggressive behaviors … in all patients.” Forty-five percent of subjects experienced “a significant decrease in cognitive impairment.” None of the patients complained of any adverse side effects. All of the patients exhibited increased quality of life and a “decrease in caregiver burden and costs of medical care and assistance.”

Authors concluded, “Our anecdotical, spontaneous, and observational study demonstrated the efficacy and safety of oil-diluted cannabis extract in patients with AD. The limitations of our study are: 1) small patient cohort, 2) absence of control group, 3) self-administered questionnaires that are the most practical but not objective instruments to assess the neurologic functions of AD patients.”

The full abstract of this study can be found below.

Abstract

Objectives: Ten million new cases of dementia are recorded annually worldwide, with agitation and idiopathic weight loss being the most common symptoms. Several pharmacological therapies have emerged in recent years, but the clinical use of cannabis extracts in older patients with AD is constantly growing. This retrospective, analytical, observational, spontaneous trial aimed to enhance the clinical action of THC: CBD cannabis extract administration in AD patients with severe symptoms such as agitation, weight loss, cognitive impairment, and sleep disturbance.

Methods: Thirty patients (9 men and 21 women) diagnosed with mild, moderate, or severe AD, aged 65-90 years, appealing to our Second Opinion Medical Consultation (Modena, Italy), were enrolled and required to use oil-diluted cannabis extract, Bedrocan® (22% THC, 0.5% CBD, Olive Oil 50 ml), twice a day for 12 weeks. The efficacy of cannabinoid therapy was evaluated at baseline and 12 weeks after therapy, employing three self-administered questionnaires completed by the parents of the enrolled patients: NPI-Q, CMAI, and MMSE.

Key findings: The NPI-Q demonstrated a reduction (p<0.0001) in agitation, apathy, irritability, sleep disturbances, and eating disturbances, consequently improving caregiver distress. Levels of physically and verbally aggressive behaviours, measured using the CMAI questionnaire, were lower (p<0.0001) in all patients. The MMSSE questionnaire confirmed a significant decrease (p<0.0001) in cognitive impairment in 45% of the patients.

Conclusion: Our anecdotical, spontaneous, and observational study demonstrated the efficacy and safety of oil-diluted cannabis extract in patients with AD. The limitations of our study are: 1) small patient cohort, 2) absence of control group, 3) self-administered questionnaires that are the most practical but not objective instruments to assess the neurologic functions of AD patients.

Thank you for reading The Marijuana Herald. You can sign up for occasional news updates using the form below.